Acute Myelogenous Lymphoma (AML)

First (CR1)/Second (CR2) Remission

**BMT330**
Phase II Very Low Dose Total Body Irradiation in Combination with Total Lymphoid Irradiation and anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-MHCT
PI: Muffy
Sponsor: Stanford

**BMT302**
Phase II Ibrutinib Maintenance After Reduced-Intensity Conditioning & Allogeneic HCT in Acute Leukemia
PI: Rezvani
Stanford

**BMT332**
Phase II FLT3 Inhibitor Gilteritinib Maintenance Therapy After Allogeneic Transplant in FLT3/ITD AML
PI: Muffy
BMT CTN

**BMT334**
Gilteritinib (ASP2215) in FLT3 Mutated Relapsed or Refractory AML or FLT3-Mutated AML in CR w/ MRD
PI: Muffy
Pending

Advanced Disease

**BMT236**
Phase II/III MAHCT w/ T Cell Depleted Graft w/ Infusion of Conventional and Regulatory T Cells PI: Meyer NIH
PI: Meyer
NIH

**BMT338**
Phase I
DonorGrafts Derived From OrcaGraft w/GVHD
Prophylaxis in MA-alloHCT in Hematologic Malignancies
PI: Johnson
Pending

First (CR1) or Higher Remission

**BMT326**
Phase III
Haploidentical HSCT & ATIR101 or Post-Transplant Cyclophosphamide in Hematologic Malignancy
PI: Johnson
Pending

**KEY**
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold